Therapeutic vaccines and cancer: focus on DPX-0907
نویسندگان
چکیده
منابع مشابه
Therapeutic vaccines and cancer: focus on DPX-0907
In an attempt to significantly enhance immunogenicity of peptide cancer vaccines, we developed a novel non-emulsion depot-forming vaccine platform called DepoVax™ (DPX). Human leukocyte antigen (HLA)-A2 restricted peptides naturally presented by cancer cells were used as antigens to create a therapeutic cancer vaccine, DPX-0907. In a phase I clinical study, the safety and immune-activating pote...
متن کاملTherapeutic vaccines for prostate cancer.
Prostate cancer is the most common, noncutaneous cancer for men in the U.S., leading to more than 30,000 deaths a year. Vaccines for prostate cancer, which for several years have been shown to generate immunologic responses, are beginning to show significant clinical promise. At present, numerous therapeutic options are being investigated, including autologous and allogeneic whole-tumor cell va...
متن کاملTherapeutic vaccines for ovarian cancer.
While therapeutic vaccines for ovarian cancer represent only a small fraction of active clinical trials, growing interest in this area and the accumulated data supporting the use of vaccines in cancer treatment portend further expansion of trials incorporating these strategies. This review explores the rationale for the use of vaccines for the treatment of ovarian cancer. It examines vaccine pl...
متن کاملTherapeutic Vaccines Against Cancer and Autoimmune Diseases
Elucidation of antigenicity and immunogenicity My laboratory pioneered the design of amino acid oligomers to define the minimal and precise chemical characteristics of antigens – molecules that could be bound by antibodies (1). Using these tools, we determined the functional size of the antibody binding pocket, and characterized the effects of charge, hydrophobicity, and side chain interactions...
متن کاملPlasma biomarker analysis of ovarian cancer patients undergoing immunotherapy with therapeutic cancer vaccine DPX-Survivac
Background Immune based therapies for cancer are emerging as promising strategies to treat a number of malignancies. A more thorough biomarker assessment of the patients may provide insights into the variability in response to such immune therapies. In a Phase I/Ib clinical trial with the survivin-targeting vaccine DPX-Survivac, we showed the induction of robust immune responses in ovarian canc...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Biologics: Targets and Therapy
سال: 2014
ISSN: 1177-5475
DOI: 10.2147/btt.s55196